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Background: Obesity is associated with the development of acute respiratory distress syndrome (ARDS) in at-risk
patients. Low plasma levels of adiponectin, a circulating hormone-like molecule, have been implicated as a possible
mechanism for this association. The objective of this study was to determine the association of plasma adiponectin
level at ICU admission with ARDS and 30-day mortality in patients with severe sepsis and septic shock.
Methods: This is a prospective cohort study of patients admitted to the medical ICU at the Hospital of the University
of Pennsylvania. Plasma adiponectin was measured at the time of ICU admission. ARDS was defined by Berlin criteria.
Multivariable logistic regression was used to determine the association of plasma adiponectin with the development
of ARDS and mortality at 30 days.
Results: The study included 164 patients. The incidence of ARDS within 5 days of admission was 45 %. The median
initial plasma adiponectin level was 7.62 mcg/ml (IQR: 3.87, 14.90) in those without ARDS compared to 8.93 mcg/ml
(IQR: 4.60, 18.85) in those developing ARDS. The adjusted odds ratio for ARDS associated with each 5 mcg increase in
adiponectin was 1.12 (95 % CI 1.01, 1.25), p-value 0.025). A total of 82 patients (51 %) of the cohort died within 30 days
of ICU admission. There was a statistically significant association between adiponectin and mortality in the unadjusted
model (OR 1.11, 95 % CI 1.00, 1.23, p-value 0.04) that was no longer significant after adjusting for potential confounders.
Conclusions: In this study, low levels of adiponectin were not associated with an increased risk of ARDS in patients
with severe sepsis and septic shock. This argues against low levels of adiponectin as a mechanism explaining
the association of obesity with ARDS. At present, it is unclear whether circulating adiponectin is involved in the
pathogenesis of ARDS or simply represents an epiphenomenon of other unknown functions of adipose tissue or
metabolic alterations in sepsis.
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Acute respiratory distress syndrome (ARDS) is a signifi-
cant complication of severe sepsis, with a mortality rate
approaching 50 % [1]. Body composition and metabolic
factors have been shown to modify the risk of developing
ARDS in at-risk patients. For example, observational stud-
ies have demonstrated association between diabetes and
decreased risk of ARDS [2–5] and between obesity and in-
creased risk of ARDS [6]. Despite the increased risk of de-
veloping ARDS, obese patients do not appear to have an
increased risk of death from ARDS and may, in fact,
have reduced mortality compared to non-obese patients
[7–10]. The mechanisms underlying why the incidence of
ARDS may be higher yet survival better in obese patients,
one example of the ‘obesity paradox’, are incompletely
understood [11, 12]. One proposed explanation is that
obesity itself primes the lung for the development of lung
injury [13].
Obese patients have alterations in the release and re-
sponse of adipokines, circulating hormone-like molecules
released from adipose tissue. Recent preclinical studies
have focused on the role of adipokines in the mechanisms
underlying obesity-associated ARDS. Adiponectin, one
such adipokine, has anti-inflammatory properties [14].
Plasma levels of adiponectin are reduced in obese com-
pared to lean individuals [15]. Adiponectin may modulate
lung inflammation through multiple pathways. Adiponec-
tin protects against systemic inflammation by promoting
the clearance of apoptotic cells by macrophages [16]. In
addition, adiponectin receptors are expressed on alveolar
macrophages and pulmonary endothelial cells though, at
present, the role of adiponectin in lung homeostasis has
not been fully elucidated [13, 17–20]. Animal studies have
suggested that adiponectin may play a lung-protective
role in the setting of infection [21, 22], leading to the
hypothesis that low levels of adiponectin in obese indi-
viduals may predispose the lung to an injury pattern,
potentiating ARDS.
Although exogenous administration of adiponectin is
protective against lung injury in animal models, the rela-
tionship between plasma adiponectin and lung injury in
human patients is less clear. Prior observations have re-
ported that higher levels of plasma adiponectin are associ-
ated with increased mortality in patients with respiratory
failure but are not associated with severity of lung disease
[23, 24]. The primary objective of this study was to deter-
mine the association between plasma adiponectin level at
admission to the intensive care unit (ICU) with the devel-
opment of ARDS in patients with severe sepsis and septic
shock. Based on preclinical studies, we hypothesized that
low adiponectin levels at the time of ICU admission would
be associated with ARDS in at-risk patients. In addition,
we sought to determine the relationship between adipo-
nectin and mortality in septic patients.Methods
Study design
The Molecular Epidemiology of Severe Sepsis in the
ICU (MESSI) study is a prospective cohort study of sep-
sis patients admitted to the medical ICU at the Hospital
of the University of Pennsylvania, an urban tertiary re-
ferral center. For this study, we included 164 consecutive
patients enrolled in the MESSI cohort from 6 January
2011 through 15 March 2012, for whom plasma samples
were available for analysis.
Study population
The MESSI cohort has been described previously [25, 26].
Patients are eligible for enrollment in the MESSI cohort if
the primary reason for ICU admission is severe sepsis as
defined by the American College of Chest Physicians
consensus definition [27]. The consensus criteria in-
clude (1) two or more systemic inflammatory response
syndrome criteria, (2) known or strongly suspected in-
fection, and (3) evidence of organ dysfunction or shock.
Exclusion criteria were lack of commitment to life-
sustaining measures at enrollment or admission from a
long-term acute care facility. For this study, we also ex-
cluded patients admitted to the ICU from an outside
hospital to ensure all plasma samples were from ICU ad-
mission. The Institutional Review Board at the University
of Pennsylvania approved the study, Protocol 808542.
This study was approved with a waiver of timely con-
sent. Consent was obtained from patients or surrogates
as soon as feasible.
Data collection
Trained research personnel collected clinical data pro-
spectively, including baseline demographics and chronic
health information. Physiologic information and labora-
tory values were collected daily over the first 6 days of
the subject’s ICU stay. Height and weight were extracted
from patient interview or the electronic medical record
to determine body mass index (BMI) at the time of ICU
admission. BMI categories were defined by the World
Health Organization (WHO) categories: BMI ≥30 kg/m2
was considered obese [28]. All plasma samples were ob-
tained from the day of ICU admission. The mean duration
between plasma sample and time when patients met cri-
teria for ARDS was 12.29 hours (range of 127.36 hours
before to 21.66 hours after ARDS criteria were met).
Adiponectin was measured in duplicate using a human
adiponectin enzyme-linked immunosorbent assay (R&D
Systems, Minneapolis, MN).
Outcome definition
The primary outcome was the development of ARDS
within 5 days of ICU admission. ARDS was defined by
Berlin criteria: acute-onset bilateral infiltrates on chest
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fully explained by cardiac failure with arterial partial
pressure of oxygen/inspired oxygen fraction (PaO2/FiO2)
≤300 [29]. Chest radiographs were independently evalu-
ated by two physician-investigators blinded to other data,
with adjudication as necessary as previously described
[30]. To be defined as having ARDS, a subject had to meet
the Berlin criteria for both radiographs and arterial blood
gas within a 24-hour period [25, 29]. Mortality at 30 days
was determined using data available in the electronic
health record. If there was no healthcare encounter within
30 days of ICU admission, we performed an online obitu-
ary search. Online obituary search was used to determine
the status of four patients (2 %) in the cohort whose vital
status was ambiguous in the medical record.
Statistical analysis
Plasma adiponectin and ARDS
Wilcoxon rank sum and chi square tests were performed
to evaluate differences in baseline characteristics be-
tween patients with ARDS and patients without ARDS.
We used Student’s t test of log-transformed adiponectin
to compare adiponectin levels in patients with and with-
out ARDS. Multivariable logistic regression was used to
determine the association between plasma adiponectin
on the day of admission and ARDS within 5 days of ICU
admission, adjusting for potential confounders. We cre-
ated two multivariable models. In the first model, we de-
cided a priori to adjust for the following covariates,
given their known association with serum adiponectin
levels: history of chronic liver disease [31, 32], diabetes
[33], and BMI [34]. BMI was included as a continuous
variable in all analyses. We also included potential con-
founders that were associated with adiponectin or ARDS
in bivariate analysis (p value <0.25) [35]. We evaluated
effect modification of the association between adiponec-
tin and ARDS by BMI using the likelihood ratio test. We
used post-estimation marginal analysis of final logistic
regression models to determine the standardized risk of
ARDS at several percentiles of plasma adiponectin [36].
In a second multivariable model, we determined the as-
sociation of plasma adiponectin with ARDS after adjust-
ing for BMI, pulmonary source of infection, history of
diabetes, and Acute Physiology and Chronic Health Evalu-
ation (APACHE) III. We also performed a subsequent un-
adjusted analysis excluding patients who developed ARDS
in the first 6 hours after the plasma sample was obtained.
Plasma adiponectin and mortality
We used multivariable logistic regression to test the
association between plasma adiponectin on the day of
ICU admission and 30-day mortality, including ARDS as a
covariate. We also created a multivariable model adjusting
for ARDS, history of chronic liver disease, diabetes, andBMI. Further confounders were considered in the final
logistic regression models if they were associated with adi-
ponectin or mortality in bivariate analysis (p value <0.25)
[35]. We evaluated effect modification of the association
between adiponectin and 30-day mortality by BMI using
the likelihood ratio test. Mortality status was unknown in
three patients. All statistical analyses were performed with
Stata/IC 13.0 (StataCorp LP, College Station, TX).
Results
The study sample included 164 patients with severe sepsis
or septic shock who required ICU admission. The inci-
dence of ARDS within 5 days of ICU admission was 45 %.
Among those patients who developed ARDS, the preva-
lence of ARDS on the day of ICU admission was 67 % and
a total of 88 % had ARDS by ICU day 2. Characteristics of
study participants are presented in Table 1. Patients who
developed ARDS had a higher median BMI compared to
those did not, but this was not statistically significant. The
incidence of ARDS was lower in diabetic patients, consist-
ent with prior studies, though this was not statistically sig-
nificant [2–4]. Those who developed ARDS were more
likely to have a history of liver disease, shock on the day of
admission, and a pulmonary source of sepsis. Patients with
ARDS also had increased severity of illness and higher 30-
day mortality compared to those patients who did not de-
velop ARDS. Patients who died were more likely to be of
white race, immunocompromised, and have a history of
liver disease (Table 2). ARDS was a significant risk factor
for mortality in this cohort.
The median initial plasma adiponectin level was 7.62
mcg/ml (IQR 3.87, 14.90) in those without ARDS com-
pared to 8.93 mcg/ml (IQR 4.60, 18.85) in those who de-
veloped ARDS (p value 0.03). Consistent with prior
studies, adiponectin level was inversely associated with
BMI (Spearman ρ –0.2, p value = 0.01). The median adipo-
nectin concentration was 7.08 mcg/ml (IQR 2.88, 11.43) in
the obese and 8.84 mcg/ml (IQR 4.56, 18.53) in the non-
obese. Adiponectin was also weakly correlated with APA-
CHE III score (Spearman ρ 0.19, p value 0.02).
The adjusted odds ratio (OR) for ARDS associated with
each 5 mcg increase in adiponectin was 1.12 (95 % CI
1.01, 1.25, p value 0.025) in a model that included BMI,
history of diabetes, pulmonary source of sepsis, and APA-
CHE III (Table 3). The adjusted OR for ARDS associated
with each 5 mcg increase in adiponectin was 1.11 (95 %
CI 1.00, 1.23, p value 0.048) in a multivariable model in-
cluding age, BMI, diabetes, history of chronic liver disease,
pulmonary source of infection, and shock at the time of
admission (Table 3). The standardized risk of ARDS hold-
ing constant all factors in the adjusted model was 40 % at
an adiponectin plasma level of 1.49 mcg/ml, representing
the 5th percentile of plasma adiponectin. This risk in-
creased to 62 % at an adiponectin level of 56.55 mcg/ml,
Table 2 Patient characteristics by 30-day mortality
Alive at 30 days (n = 79) Died at 30 days (n = 82) P value
Age, median (IQR) 61 (54, 71) 63 (53, 70) 0.82
Female sex, n (%) 34 (43) 31 (38) 0.50
White race, n (%) 33 (42) 54 (66) 0.002
Body mass index, median (IQR) 25.0 (21.6, 30.6) 24.5 (20.7, 30.2) 0.42
History of diabetes, n (%) 32 (41) 24 (29) 0.13
History of chronic liver disease, n (%) 3 (4) 15 (18) 0.004
History of chronic kidney disease, n (%) 8 (10) 10 (12) 0.66
Immunocompromised, n (%) 33 (42) 50 (61) 0.02
History of organ transplant, n (%) 6 (8) 6 (7) 0.96
Pulmonary source of sepsis, n (%) 27 (34) 36 (44) 0.21
Shock on admission, n (%) 47 (59) 57 (68) 0.25
ARDS, n (%) 19 (24) 54 (66) <0.001
Values obtained using Wilcoxon rank sum and chi square tests. ARDS acute respiratory distress syndrome
Table 1 Patient characteristics by ARDS status
Non-ARDS (n = 90) ARDS (n = 73) P-value
Age (median, IQR) 63 (55, 72) 58 (52, 68) 0.09
Female sex (n, %) 35 (39) 31 (42) 0.64
White race (n, %) 48 (53) 41 (56) 0.72
Tobacco use (n, %) 0.81
Never smoker 24 (27) 22 (30)
Ever smoker 54 (60) 39 (53)
Current smoker 9 (10) 8 (11)
Unknown 3 (3) 4 (5)
BMI (median, IQR) 23.6 (20.3, 28.6) 25.6 (21.3, 31.0) 0.15
Weight class (n, %) 0.14
BMI ≤18.5 kg/m2 11 (12) 8 (11)
BMI 18.5–25 kg/m2 43 (48) 23 (32)
BMI 25–30 kg/m2 18 (20) 19 (26)
BMI ≥30 kg/m2 18 (20) 23 (32)
History of diabetes (n, %) 37 (41) 21 (28) 0.10
History of chronic liver disease (n, %) 4 (4) 14 (19) 0.003
History of chronic kidney disease (n, %) 9 (10) 9 (12) 0.66
Immunocompromised (n, %) 44(49) 38 (52) 0.69
History of organ transplantation (n, %) 8 (9) 4 (6) 0.42
Pulmonary source of sepsis (n, %) 25 (28) 38 (52) 0.002
Shock on Admission (n, %) 51 (57) 54 (74) 0.03
APACHE III (median, IQR) 72 (61, 90) 85 (73, 98) 0.003
30-day mortality (n, %) 28 (32) 54 (74) <0.001
Values obtained using Wilcoxon ranksum and chi square tests. Abbreviations: ARDS = Acute Respiratory Distress Syndrome; BMI = Body Mass Index; APACHE = Acute
Physiology, Age, Chronic Health Evaluation
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Table 3 Multivariable analyses of association of adiponectin
levels at admission with ARDS
Odds ratio per 5 mcg/ml increase
in adiponectin (95 % CI)
P value
Unadjusted 1.12 (1.01, 1.23) 0.027
Multivariable model 1a 1.12 (1.01, 1.25) 0.025
Multivariable model 2b 1.11 (1.00, 1.23) 0.048
aAdjusted for diabetes, body mass index (BMI), pulmonary source of sepsis,
Acute Physiology and Chronic Health Evaluation III. bAdjusted for age,
diabetes, BMI, history of liver disease, pulmonary source of sepsis, and shock
at time of admission. ARDS acute respiratory distress syndrome
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the cohort (Fig. 1). There was no evidence of effect modi-
fication by BMI on the association between adiponectin
and ARDS (p value for interaction term 0.50).
In a sensitivity analysis, we examined the association
between plasma adiponectin and ARDS after excluding
patients who met the criteria for ARDS within the first
6 hours after the plasma sample was obtained [37]. We
were missing the time stamp for one plasma sample and
this patient was excluded from this analysis. A total of
90 patients did not develop ARDS, 41 patients met the
criteria for ARDS within 6 hours of admission, and 31
met the criteria for ARDS at least 6 hours after their ini-
tial plasma sample was obtained. After excluding the 41
patients who developed ARDS within the first 6 hours,
the unadjusted OR for ARDS associated with each 5
mcg increase in adiponectin was 1.13 (95 % CI 1.00, 1.28
p value 0.056).
A total of 82 patients (51 %) from the cohort died within
30 days of ICU admission. There was a statistically signifi-
cant association between adiponectin and mortality in the
unadjusted model (OR 1.11, 95 % CI 1.00, 1.23, p value
0.04). In a model adjusted for ARDS, the association be-
tween adiponectin and mortality was attenuated (OR 1.08,
95 % CI 0.96, 1.21, p value 0.19) (Table 4). In the completeFig. 1 Standardized risk of acute respiratory distress syndrome (ARDS) by pmultivariable model adjusting for BMI, race, history of
diabetes, history of liver disease, immunocompromised
status, pulmonary source of infection, and ARDS, the as-
sociation was further attenuated (OR 1.02, 95 % CI 0.92,
1.15, p value 0.66) (Table 4). There was no effect modifica-
tion by BMI (p value for interaction term 0.29).
Discussion
In this study, we found that low plasma levels of adiponec-
tin at the time of admission to the intensive care unit were
not associated with the development of ARDS in patients
with severe sepsis or septic shock. In contrast, patients
with ARDS on admission, or who later developed ARDS,
demonstrated higher plasma adiponectin levels than those
patients without ARDS. In addition, we found high plasma
adiponectin was associated with 30-day mortality in bi-
variate analysis; this association was no longer significant
in a multivariable model including ARDS.
Adiponectin is a highly abundant circulating hormone
with pleotropic effects on numerous endocrine functions
and cell types. Plasma levels of adiponectin are reduced in
obese individuals likely due to selective suppression of its
synthesis in adipocytes [15]. Animal studies have sug-
gested that adiponectin may play a lung protective role in
the setting of sepsis. For example, adiponectin-deficient
mice were found to have profoundly reduced survival in
response to cecal ligation and puncture [21] and adipo-
nectin administration was shown to attenuate lung injury
in an endotoxin (lipopolysacchararide, LPS) animal model
[22]. Shah et al. studied three distinct animal models
of hypoadiponectinemia and found all three models
were more susceptible to developing lung injury from
LPS when compared with wild-type/lean animals [38].
Repletion of adiponectin protected against the develop-
ment of this lung injury, leading the authors to suggest
that low serum adiponectin levels should be tested as aercentile of plasma adiponectin in cohort
Table 4 Multivariable analyses of association between
adiponectin levels at admission and mortality
Odds ratio per 5mcg/ml increase
in adiponectin (95 % CI)
P value
Unadjusted 1.11 (1.00, 1.23) 0.04
Adjusted for ARDS 1.08 (0.96, 1.21) 0.19
Multivariable modela 1.02 (0.92, 1.15) 0.66
aAdjusted for history of liver disease, diabetes, body mass index, race,
immunocompromised status, pulmonary source of infection, and acute
respiratory distress syndrome (ARDS)
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ARDS [38].
Whereas animal data implicate low adiponectin states
as potentiating lung injury, our study and others in hu-
man populations do not endorse an association between
low circulating adiponectin and adverse outcomes. In a
population of critically ill patients requiring mechanical
ventilation, 21 % of whom had ARDS, high serum adipo-
nectin levels at admission were associated with increased
28-day mortality [24]. In a subsequent analysis of plasma
samples from over 800 patients with established ARDS,
there was no relationship between baseline adiponectin
level and severity of illness, severity of lung injury, or
mortality, though higher adiponectin levels were associ-
ated with mortality among patients with non-pulmonary
but not direct pulmonary ARDS [23]. Finally, Ahasic and
colleagues examined the association between genetic
variations in adiponectin genes and survival in ARDS
[39]. These authors observed increased mortality among
patients with ARDS in homozygotes for the rs2082940
variant of adiponectin. Plasma adiponectin levels were
not reported for Ahasic’s study, however this variant has
been previously shown to be associated with increased
ambulatory levels of adiponectin [40].
To our knowledge, ours is the first study to examine
plasma adiponectin levels with the development of
ARDS in patients admitted to the ICU with severe sepsis
or septic shock. Our finding that low plasma adiponectin
levels are not associated with ARDS is in contrast to re-
sults from models of LPS-induced lung injury in obesity-
prone mice, where exogenous adiponectin upregulated
vascular barrier-enhancing molecules and attenuated
lung injury [38]. Our results argue against low circulat-
ing adiponectin as a mediator of the observed increase
in ARDS risk faced by obese patients. Furthermore, our
findings argue against low adiponectin level at the time
of admission as a marker for identifying patients at in-
creased risk of developing ARDS. Whereas high levels of
adiponectin in ambulatory patients are associated with
vascular protection and reduced risk of myocardial in-
farction [41], the significance of very high levels during
critical illness are unknown. Our group and others havedemonstrated differential gene and plasma regulation of
inflammation during resting and evoked states [42–45]
and it may be that adiponectin has pleiotropic effects in
different contexts. Alternatively, it may be that high cir-
culating levels of adiponectin reflect some level of stress
detected by adipocytes without implicating a causal role
for adiponectin in the development of ARDS or for
mortality in ARDS. Future mechanistic studies will be
necessary to delineate whether sepsis-evoked adiponectin
response serves vascular barrier-enhancing functions in
this context.
We found high plasma adiponectin was associated with
30-day mortality in bivariate analysis consistent with prior
studies that have also found an association between high
adiponectin levels and increased mortality. Koch et al.
found higher baseline adiponectin levels were associated
with increased ICU mortality in a cohort of patients with
sepsis, independent of BMI [46]. Similarly, Walkey re-
ported that high adiponectin levels early in respiratory
failure are associated with mortality, with no effect modifi-
cation by BMI [24]. In our cohort of patients with severe
sepsis and septic shock, the association of high adiponec-
tin with mortality was no longer significant after adjusting
for ARDS. In the context of these prior studies, it is pos-
sible that the reason we did not find an association in the
multivariable model is that ARDS is on the causal path-
way for the association between plasma adiponectin
level and mortality.
There are several limitations to our study. This co-
hort comprised patients from a single academic center
that serves as a large referral center for oncology and
transplant patients. As such, our cohort includes a high
proportion of immunocompromised patients, which
may limit the generalizability of our findings. Misclassi-
fication of BMI class is possible in our cohort. BMI is
an imperfect measure in the ICU where weight often
reflects the acute illness or fluid resuscitation, and
height may be erroneously recorded in the supine pa-
tient. We used weight measurements collected at the
time of admission to minimize the effects of critical
illness and fluid resuscitation on this measurement. In
addition, we were unable to control for glucose intake
or insulin administration immediately prior to plasma
analysis. Given our samples are drawn from the time of
admission, we do not expect this to have a significant
impact on our results. We only measured one adipo-
kine in this study and did not perform fractionation stud-
ies. Adiponectin circulates in three main forms: trimers,
hexamers, and high-molecular weight multimers [14]. Fu-
ture studies could examine the association between differ-
ent sub-fractions of adiponectin and ARDS. Further, the
relationship between adiponectin and other biomarkers of
endothelial activation, such as von Willebrand factor and
angiopoietin-2, may be important to explore [47, 48].
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in interpreting our results. We do not have plasma sam-
ples available for this cohort prior to the onset of sepsis
and it is possible these patients initially had low levels of
plasma adiponectin that increased in response to sepsis.
However, after excluding patients who met the criteria
for ARDS in the first 6 hours after the plasma sample
was obtained, the association between high plasma adi-
ponectin levels and ARDS demonstrated a similar effect
size. While we cannot implicate a causal role for adipo-
nectin in the pathogenesis of ARDS from these results,
further mechanistic studies should be performed to
understand the role of adiponectin in the development
of lung injury.
This study has several strengths. This was a well-
characterized and diverse cohort of septic patients,
with careful outcome ascertainment. The ARDS pheno-
type was determined by multiple-physician consensus
review. Prior studies examining the association be-
tween plasma adiponectin and patient outcomes have
included plasma samples from patients previously enrolled
in randomized controlled trials [23, 24]. Our study adds to
this literature in several important ways. First, this cohort
includes a diverse group of patients with sepsis allowing us
to examine the association between plasma adiponectin
and the development of ARDS in addition to the outcome
of mortality. In addition, our study is an observational co-
hort study and includes many patients who typically would
not be enrolled in randomized controlled trials and may
have important differences compared to the enrolled crit-
ically ill trial population [49]. Finally, plasma samples were
available from the time of admission to the ICU in our
cohort, allowing us to examine plasma adiponectin
levels at a time when screening for at-risk patients
would be feasible and at a time point earlier than
plasma sample analysis in randomized controlled trials.
In the ARDS Network Fluid and Catheter Treatment
Trial (FACTT), the source of plasma samples for the
study by Walkey et al. that examined the association of
adiponectin with patient outcomes, the mean time be-
tween admission to the ICU and first protocol instruction
was approximately 42 hours [50].
Conclusions
We found that high plasma levels of adiponectin are as-
sociated with ARDS in patients with severe sepsis and
septic shock. This association was independent of BMI.
At present, it is unclear whether circulating adiponectin
is involved in the pathogenesis of ARDS or simply repre-
sents an epiphenomenon of other unknown functions of
adipose tissue or metabolic alterations in sepsis. Mech-
anistic studies are needed to further understand the
alterations in release and response of adiponectin in
sepsis and its role in the development of lung injury.Key messages
 Low plasma adiponectin levels at the time of ICU
admission were not associated with ARDS in human
patients with severe sepsis and septic shock
 The association between plasma adiponectin levels
and ARDS is independent of BMI
 Further research is needed to determine whether
circulating adiponectin has a pathogenic role in the
development of ARDS
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